门冬胰岛素和生物合成人胰岛素在妊娠期糖尿病治疗中的疗效分析  

Efficacy of Insulin Aspartate and Biosynthetic Human Insulin in the Treatment of Gestational Diabetes Mellitus

作　　者：张波兰 ZHANG Bolan(Department of Obstetrics,Jiexi County People's Hospital,Jieyang 515400,Guangdong,China)

机构地区：[1]广东省揭西县人民医院产科,广东揭阳515400

出　　处：《糖尿病新世界》2024年第8期112-115,共4页Diabetes New World Magazine

摘　　要：目的分析在妊娠期糖尿病(Gestational Diabetes Mellitus,GDM)治疗中,门冬胰岛素(诺和锐)与生物合成人胰岛素(诺和灵R)的应用效果。方法选取2020年3月-2023年12月广东省揭西县人民医院产科收治的82例GDM患者为研究对象,遵循随机抽样法分为对照组(诺和灵R治疗)、研究组(诺和锐治疗),各41例。比较两组血糖变化情况、血糖达标时间和日胰岛素总量及妊娠结局。结果治疗前两组血糖变化情况比较,差异无统计学意义(P>0.05);治疗后,研究组糖化血红蛋白与餐后2 h血糖水平低于对照组,差异有统计学意义(P均<0.05);治疗后两组空腹血糖比较,差异无统计学意义(P>0.05)。研究组血糖达标时间短于对照组,日胰岛素总量少于对照组,差异有统计学意义(P均<0.05)。研究组低体重儿、早产发生率低于对照组,差异有统计学意义(P均<0.05)。两组胎儿窘迫发生率比较,差异无统计学意义(P>0.05)。结论门冬胰岛素相较于生物合成人胰岛素在控制GDM患者餐后血糖中更为有效,并且血糖达标用时短以及胰岛素用量少,并有利于改善母婴结局。Objective To analyze the effects of insulin aspartate(Novolin)and biosynthetic human insulin(Novolin R)in the treatment of gestational diabetes mellitus(GDM).Methods A total of eighty-two GDM patients admitted to the obstetrics department of Jiexi County People's Hospital of Guangdong Province from March 2020 to December 2023 were selected as the study objects,and were divided into control group(treated with Novolin R)and study group(treated with Novolin)according to random sampling method,with forty-one cases each.The changes of blood glucose,the time of blood glucose standard,the total amount of daily insulin and the pregnancy outcome were compared be-tween the two groups.Results There was no significant difference in the changes of blood glucose between the two groups before treatment(P>0.05).After treatment,the levels of glycated hemoglobin A1c and 2-hour postprandial plasma glucose in the study group were lower than those in the control group,and the differences were statistically sig-nificant(both P<0.05).There was no significant difference in fasting plasma glucose between the two groups after treatment(P>0.05).The blood glucose standard time of the study group was shorter than that of the control group,and the total daily insulin was less than that of the control group,and the differences were statistically significant(both P<0.05).The incidence of low birth weight infants and premature birth in the study group was lower than that in the con-trol group,and the difference was statistically significant(both P<0.05).There was no significant difference in the inci-dence of fetal distress between the two groups(P>0.05).Conclusion Compared with biosynthetic human insulin,insu-lin aspartate is more effective in controlling postprandial blood glucose in GDM patients,and the time required to reach blood glucose level is shorter and the amount of insulin is less,which is conducive to improving maternal and in-fant outcomes.

关 键 词：妊娠期糖尿病 血糖 生物合成人胰岛素 门冬胰岛素 

分 类 号：R587.1[医药卫生—内分泌]